Cancer Immunotherapy: CAR T as ‘Car Race’ – Genetic Engineering & Biotechnology News (blog)
|
Cancer Immunotherapy: CAR T as 'Car Race'
Genetic Engineering & Biotechnology News (blog) Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics' halting development of JCAR015? How could some second-tier … |
